These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38310289)

  • 41. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
    PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
    Sarkhosh-Inanlou R; Imani M; Sam MR
    Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
    Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
    Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
    Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
    BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
    Gulhati P; Zaytseva YY; Valentino JD; Stevens PD; Kim JT; Sasazuki T; Shirasawa S; Lee EY; Weiss HL; Dong J; Gao T; Evers BM
    Carcinogenesis; 2012 Sep; 33(9):1782-90. PubMed ID: 22696593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
    Bando H; Yoshino T; Shinozaki E; Nishina T; Yamazaki K; Yamaguchi K; Yuki S; Kajiura S; Fujii S; Yamanaka T; Tsuchihara K; Ohtsu A
    BMC Cancer; 2013 Sep; 13():405. PubMed ID: 24006859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
    Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
    Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
    Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
    Ciardiello F; Normanno N; Maiello E; Martinelli E; Troiani T; Pisconti S; Giuliani F; Barone C; Cartenì G; Rachiglio AM; Montesarchio V; Tonini G; Rizzi D; Cinieri S; Bordonaro R; Febbraro A; De Vita F; Orditura M; Fenizia F; Lambiase M; Rinaldi A; Tatangelo F; Botti G; Colucci G
    Ann Oncol; 2014 Sep; 25(9):1756-1761. PubMed ID: 24942275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
    Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
    Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer.
    Wang C; Pan D
    J Clin Lab Anal; 2022 Jun; 36(6):e24444. PubMed ID: 35435290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
    Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
    Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
    PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.